The Utility of the BRCAvantage Test
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Clinical Pearls
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
- BRCAvantage was launched in mid-October
- The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
- BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations
<<<
Recent Videos
Related Content
Subcutaneous Daratumumab Significantly Delays Progression in Smoldering Myeloma
December 9th 2024Article
Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS compared with active monitoring in patients with smoldering multiple myeloma.
Read More
